The estimated Net Worth of John T Henderson is at least $2.01 Milion dollars as of 25 April 2024. John Henderson owns over 10,562 units of Myriad Genetics stock worth over $842,800 and over the last 21 years he sold MYGN stock worth over $681,671. In addition, he makes $482,488 as Independent Director at Myriad Genetics.
Sign up
John Henderson MYGN stock SEC Form 4 insiders trading
John has made over 26 trades of the Myriad Genetics stock since 2004, according to the Form 4 filled with the SEC. Most recently he sold 10,562 units of MYGN stock worth $681,671 on 25 April 2024.
The largest trade he's ever made was exercising 40,000 units of Myriad Genetics stock on 10 December 2012 worth over $268,000. On average, John trades about 3,455 units every 83 days since 2004. As of 25 April 2024 he still owns at least 32,070 units of Myriad Genetics stock.
You can see the complete history of John Henderson stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
John Henderson biography
Dr. John T. Henderson M.D. is no longer serves as Independent Director of the Company effective 12/2020. Dr. Henderson has served as a consultant to the pharmaceutical industry as President of Futurepharm LLC. Dr. Henderson currently serves on the Board of Directors of Cytokinetics, Inc. Until his retirement in December 2000, he was with Pfizer for over 25 years, most recently as a Vice President in the Pfizer Pharmaceuticals Group. Dr. Henderson previously held vice presidential level positions with Pfizer in Research and Development in Europe and later in Japan. He also was Vice President, Medical for the Europe, U.S. and International Pharmaceuticals groups at Pfizer. He earned his bachelor’s and medical degrees from the University of Edinburgh and is a Fellow of the Royal College of Physicians (Ed.).
What is the salary of John Henderson?
As the Independent Director of Myriad Genetics, the total compensation of John Henderson at Myriad Genetics is $482,488. There are 9 executives at Myriad Genetics getting paid more, with R. Bryan Riggsbee having the highest compensation of $3,138,980.
How old is John Henderson?
John Henderson is 75, he's been the Independent Director of Myriad Genetics since 2020. There are 1 older and 25 younger executives at Myriad Genetics. The oldest executive at Myriad Genetics, Inc. is Walter Gilbert, 87, who is the Independent Vice Chairman of the Board.
What's John Henderson's mailing address?
John's mailing address filed with the SEC is 350, Oyster Point Boulevard, South San Francisco, San Mateo County, California, 94080, United States.
Insiders trading at Myriad Genetics
Over the last 22 years, insiders at Myriad Genetics have traded over $51,783,466 worth of Myriad Genetics stock and bought 61,160 units worth $1,252,955 . The most active insiders traders include Jerry S Lanchbury, Peter D Meldrum a Arthur H Jr Hayes. On average, Myriad Genetics executives and independent directors trade stock every 18 days with the average trade being worth of $563,312. The most recent stock trade was executed by Heinrich Dreismann on 9 September 2024, trading 10,000 units of MYGN stock currently worth $270,500.
What does Myriad Genetics do?
myriad genetics inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. myriad is focused on three strategic imperatives: maintaining leadership in an expanding hereditary cancer market, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets. for more information on how myriad is making a difference, please visit the company's website: www.myriad.com.
What does Myriad Genetics's logo look like?
Complete history of John Henderson stock trades at Cytokinetics Inc a Myriad Genetics
Myriad Genetics executives and stock owners
Myriad Genetics executives and other stock owners filed with the SEC include:
-
R. Bryan Riggsbee,
Chief Financial Officer, Executive Vice President, Treasurer -
Bernard Tobin,
President - Myriad Autoimmune -
Jerry Lanchbury,
Chief Scientific Officer -
Paul J. Diaz,
CEO, Pres & Director -
R. Bryan Riggsbee,
Exec. VP, CFO & Treasurer -
Dr. Jerry S. Lanchbury Ph.D.,
Chief Scientific Officer -
Dr. Jerry S. Lanchbury,
Chief Scientific Officer -
Mark S. Verratti,
Pres of Myriad Neuroscience & Autoimmune -
Nicole Lambert,
Chief Operating Officer -
John Henderson,
Independent Director -
S. Louise Phanstiel,
Independent Chairman of the Board -
Dennis Langer,
Independent Director -
Heiner Dreismann,
Independent Director -
Lawrence Best,
Independent Director -
Walter Gilbert,
Independent Vice Chairman of the Board -
Daniel Spiegelman,
Independent Director -
Daniel Skovronsky,
Independent Director -
Colleen Reitan,
Independent Director -
Lee Newcomer,
Independent Director -
Rashmi Kumar,
Independent Director -
Mark Pollack,
Chief Medical Officer -
Gary King,
Executive Vice President - International Operations -
Benjamin Jackson,
Executive Vice President, General Counsel, Secretary -
Mark Verratti,
President - Myriad Neuroscience -
Ralph McDade,
President - Myriad RBM -
Nicole Lambert,
President - Myriad Oncology -
Paul Diaz,
President, Chief Executive Officer, Director -
Pamela Wong,
Chief Legal Officer -
Nathan Smith,
Sr. VP of Investor Relations & Treasury -
Dr. Kevin Richard Haas,
Chief Technology Officer -
Paul Chip Parkinson,
Exec. VP of Reimbursement Strategy -
Jayne Baird Hart,
Exec. VP of HR -
Dr. Clivetty Martinez,
Chief Compliance Officer -
Benjamin Jackson,
Exec. VP, Gen. Counsel & Sec. -
Scott Gleason,
Sr. VP of Investor Relations -
Kevin Richard Haas,
Chief Technology Officer -
Alexander Ford,
Chief Operating Officer -
Kevin Richard Haas,
Chief Technology Officer -
Heinrich Dreismann,
Director -
Richard Wenstrup,
Chief Medical Officer -
Virginia Drosos,
President Assurex Health -
Richard M Marsh,
V.P., General Counsel -
Mark Christopher Capone,
President & C.E.O. -
Samraat S. Raha,
Chief Operating Officer -
Pamela Wong,
Chief Legal Officer -
Walter Lloyd Sanders,
President Myriad Oncology -
Linda S Wilson,
Director -
Mark H Skolnick,
Chief Scientific Officer -
Gerald P. Belle,
Director -
Adrian N Hobden,
President -
W Wayne Laslie,
Chief Operating Officer, MPI -
Robert S Attiyeh,
Director -
Dale A Stringfellow,
Director -
Arthur Hull Jr Hayes,
Director -
Arthur H Jr Hayes,
Director -
William A Iii Hockett,
Vice President -
Gregory C Critchfield,
President -
Jay M Moyes,
Chief Financial Officer -
S George Simon,
Vice President -
Robert Gardner Harrison,
Chief Information Officer -
Ronald S. Rogers,
Exec VP Corp Communications -
James S Evans,
V.P. Finance -
T Craig Benson,
President, Myriad RBM -
Paul Bisaro,
Director -
Eric Santa,
Former Chief Growth Officer -
Paul Parkinson,
Fmr EVP Strategy & Innovation -
Margaret Ancona,
SVP, Chief of Staff -
Dale Muzzey,
Chief Scientific Officer -
Natalie Munk,
Chief Accounting Officer -
Heinrich Dreismann,
Director -
Jayne B. Hart,
See Remarks -
Shereen Solaiman,
Chief People Officer -
Scott J. Leffler,
Chief Financial Officer -
Jennifer Lynne Fox,
Chief Legal Officer